China Medicine Corporation Obtains Australian Patent for rADTZ

    GUANGZHOU, China, July 17 /Xinhua-EMWNews/ -- China Medicine

Corporation (OTC Bulletin Board: CHME; "China Medicine" or "the Company"),

a leading distributor and developer of ethical and over-the-counter drugs,

traditional Chinese medicines (TCMs), nutritional and dietary supplements,

medical devices, and medical formulations in the People's Republic of China

(PRC), announced today that it obtained a patent from Australia Patent

Office for recombinant Aflatoxin Detoxifizyme (rADTZ). The patent is valid

through January 13, 2025.



    rADTZ is an innovative product that has the potential to detoxify

aflatoxin (AFT), a potential cancer causing agent, in food and feed. It is

a compound that is a derivation of aflatoxin-detoxifizyme (ADTZ), an

extracellular enzyme. Developed by Guangzhou Co-Win Bioengineering Co.,

Ltd, a subsidiary of China Medicine, rADTZ can be used as an additive to

remove aflatoxins from animal feed as well as other food products. The

Company intends to develop rADTZ for this and other applications.



    "We are proud to announce that we have achieved a major milestone in

being granted a patent for rADTZ in Australia," said Mr. Senshan Yang,

Chairman and CEO of China Medicine. "This is a major breakthrough for China

Medicine and it opens up the opportunity to expand our business overseas,"

he added. China Medicine has already obtained a patent for rADTZ from the

State Intellectual Property Office of China in early 2004.



    China Medicine has performed laboratory experiment on rADTZ and has

gathered important data to address technological challenges related to its

development. The Company is currently testing rADTZ on animal feed and is

scheduled to begin working with the Chinese Department of Agriculture on a

large scale experiment in order to meet national standards and apply for

production permits. Once the Company receives production permits, it

expects to begin trial sales of rADTZ by the end of 2008.

    About China Medicine Corporation



    China Medicine Corporation is a leading pharmaceutical company which

discovers and develops medical formulations and distributes over 2,200

pharmaceutical products in China including prescription and over the

counter ("OTC") drugs, traditional Chinese medicine products, herbs and

dietary supplements. The Company distributes the products to wholesale

distributors in 28 provinces, more than 300 hospitals, 500 medicine

companies, and 1,788 drug stores throughout China. The Company actively

develops a number of proprietary products for many uses including oncology,

high blood pressure and the removal of toxins from food and animal feeds.

For more information visit the Company's website at

http://www.chinamedicinecorp.com .



    Cautionary Statement



    This press release contains forward-looking statements concerning the

Company's business and products. The Company's actual results may differ

materially depending on a number of risk factors including, but not limited

to, the following: general economic and business conditions, obtaining

regulatory approval for new products, the expected contribution of higher

margin products, government support for rural health care, competition from

existing and new competitors, changes in technology, and various other

factors beyond its control. All forward-looking statements are expressly

qualified in their entirety by this Cautionary Statement and the risks

factors detailed in the Company's reports filed with the Securities and

Exchange Commission. China Medicine Corporation undertakes no duty to

revise or update any forward- looking statements to reflect events or

circumstances after the date of this release.






    For more information, please contact:



    Company Contact:

     Ms. Huizhen Yu

     Chief Financial Officer

     China Medicine Corp.

     Tel:   +86-20-8739-1718

     Email: konzern08@163.com

     Web:   http://www.chinamedicinecorp.com



    Investor Relations Contact:

     Mr. Crocker Coulson, President

     CCG Investor Relations

     Tel:   +1-646-213-1915 (New York)

     Email: crocker.coulson@ccgir.com



     Mr. Richard Micchelli, Financial Writer

     Tel: +1-646-454-4516

     Email: richard.micchelli@ccgir.com

     Web:   http://www.ccgir.com